A drug called STI-571, now being tested in clinics to treat a rare form of leukemia, selectively blocks a mutant enzyme that causes the disease without harming its molecular cousins. Reporting in the Sept. 15 issue of Science, a team of researchers from the Howard Hughes Medical Institute at The ...